These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31919076)

  • 1. WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.
    Hu J; Wang T; Xu J; Wu S; Wang L; Su H; Jiang J; Yue M; Wang J; Wang D; Li P; Zhou F; Liu Y; Qing G; Liu H
    Haematologica; 2021 Jul; 106(7):1816-1827. PubMed ID: 31919076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
    Ghelli Luserna Di Rorà A; Beeharry N; Imbrogno E; Ferrari A; Robustelli V; Righi S; Sabattini E; Verga Falzacappa MV; Ronchini C; Testoni N; Baldazzi C; Papayannidis C; Abbenante MC; Marconi G; Paolini S; Parisi S; Sartor C; Fontana MC; De Matteis S; Iacobucci I; Pelicci PG; Cavo M; Yen TJ; Martinelli G
    J Hematol Oncol; 2018 Aug; 11(1):99. PubMed ID: 30068368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
    Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Garcia TB; Fosmire SP; Porter CC
    Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
    Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
    Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
    Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
    BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
    Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
    Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.
    Magnussen GI; Emilsen E; Giller Fleten K; Engesæter B; Nähse-Kumpf V; Fjær R; Slipicevic A; Flørenes VA
    BMC Cancer; 2015 Jun; 15():462. PubMed ID: 26054341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.
    Ghelli Luserna Di Rorà A; Bocconcelli M; Ferrari A; Terragna C; Bruno S; Imbrogno E; Beeharry N; Robustelli V; Ghetti M; Napolitano R; Chirumbolo G; Marconi G; Papayannidis C; Paolini S; Sartor C; Simonetti G; Yen TJ; Martinelli G
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
    Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
    Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.
    Baran N; Lodi A; Dhungana Y; Herbrich S; Collins M; Sweeney S; Pandey R; Skwarska A; Patel S; Tremblay M; Kuruvilla VM; Cavazos A; Kaplan M; Warmoes MO; Veiga DT; Furudate K; Rojas-Sutterin S; Haman A; Gareau Y; Marinier A; Ma H; Harutyunyan K; Daher M; Garcia LM; Al-Atrash G; Piya S; Ruvolo V; Yang W; Shanmugavelandy SS; Feng N; Gay J; Du D; Yang JJ; Hoff FW; Kaminski M; Tomczak K; Eric Davis R; Herranz D; Ferrando A; Jabbour EJ; Emilia Di Francesco M; Teachey DT; Horton TM; Kornblau S; Rezvani K; Sauvageau G; Gagea M; Andreeff M; Takahashi K; Marszalek JR; Lorenzi PL; Yu J; Tiziani S; Hoang T; Konopleva M
    Nat Commun; 2022 May; 13(1):2801. PubMed ID: 35589701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis.
    Wang F; Zhu Y; Huang Y; McAvoy S; Johnson WB; Cheung TH; Chung TK; Lo KW; Yim SF; Yu MM; Ngan HY; Wong YF; Smith DI
    Oncogene; 2005 Jun; 24(24):3875-85. PubMed ID: 15735666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma.
    Bhattacharya A; Schmitz U; Wolkenhauer O; Schönherr M; Raatz Y; Kunz M
    Oncogene; 2013 Jun; 32(26):3175-83. PubMed ID: 22847610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.